Publication | Open Access

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

Phase I/ii StudyMedicinePharmacologyBronchial NeoplasmSurvivin SuppressorAnti-cancer AgentCancer TreatmentSepantronium BromideOncologyRadiation OncologyLung Cancer